Pharming Reports Strong Third Quarter 2026 Growth Driven by Joenja and RUCONEST
Pharming (PHAR) reported robust third-quarter 2026 financial results, highlighted by a 21% year-over-year increase in total revenue to $117.6 million. The company's operating profit surged by 89% to $29.9 million, benefiting from disciplined expense management and strong sales of its rare disease treatments. A key driver was the Joenja therapy, which saw a 58% revenue increase to $23.8 million due to international expansion and new pediatric approvals. The company also noted a successful rebound for RUCONEST, which grew 14% to $93.8 million as patient demand stabilized despite oral competition. With $190.9 million in cash on hand, Pharming is well-positioned to fund its clinical pipeline, specifically targeting the much larger Common Variable Immune Deficiency (CVID) market with leniolisib. This strategic expansion into broader immunology markets provides a significant long-term growth runway.
Tickers: $PHAR
Topics: operating profit quarterly earnings rare disease treatments revenue growth
Read the full article at Motley Fool
Part of the story Geron Corp Reports Third Quarter 2026 Profitability Driven by RYTELO Growth (15 articles)